PT-141 (Vyleesi)
10mg
❄️Lyophilized powder (not reconstituted)
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €40.49 |
| 11 - 20 | 15% | €38.24 |
| 21+ | 20% | €35.99 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €44.99
PT-141 is supplied as a catalogued research material in 10 mg.
PT-141 denotes bremelanotide, a conformationally constrained melanocortin-receptor ligand. Registry values commonly describe the free active moiety, while manufactured material may be an acetate form with batch-dependent acetate stoichiometry. The supplied form must be confirmed by CoA and intact-mass data [1,2].
Chemical properties and registry information
| Property | Value |
|---|---|
| Name and synonyms | Bremelanotide, Vyleesi |
| Material category | Melanocortin receptor agonist |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular formula | C50H68N14O10 |
| Average molecular mass | 1025.18 g/mol |
| CAS Registry Number | 189691-06-3 |
| PubChem CID | CID 9832739 |
| Structural features | Cyclic heptapeptide with a lactam bridge between the side chains of Asp and Lys. N-terminal is acetylated. Contains non-standard amino acids Norleucine (Nle) and D-Phenylalanine (D-Phe). |
| Appearance | White to off-white lyophilised powder |
| Solubility | Soluble in bacteriostatic or sterile water. |
| Physical form | Catalogue vial; exact salt/counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
Registry values apply only to the specific molecular entity, sequence, termini and material form. Batch records take precedence over family-level literature identifiers.
PT-141 is a synthetic analog of alpha-Melanocyte-stimulating hormone (α-MSH). It is the active metabolite of Melanotan II, but lacks the C-terminal amide group, having a carboxyl terminus instead.
Research background and published evidence
Published research
The defined research context is melanocortin-receptor binding, receptor-subtype selectivity and cell-signalling assay development. The cyclic scaffold is suitable for structure–activity and analytical comparison with related melanocortin ligands [1–3].
Current scientific understanding
Published pharmacology and documents for an authorised acetate medicinal product do not authenticate this catalogue lot and do not establish equivalence, safety or suitability. No human-use outcome may be inferred from receptor-assay literature.
Bremelanotide is an established medicinal active substance in some jurisdictions.
Technical comparison
| Aspect | This catalogue material | Comparator |
|---|---|---|
| Identity | Bremelanotide/PT-141 free-acid core, subject to salt confirmation | Melanotan II, a related but distinct cyclic melanocortin peptide |
| Structural distinction | C-terminal free acid | C-terminal amide and different exact molecular identity |
| Analytical implication | Confirm lactam connectivity, free acid and counter-ion | Requires its own sequence-, termini- and salt-specific reference |
Quality and testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory handling and storage
Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution's approved procedures.
Regulatory and legal status
| Research-use notice | This material is supplied exclusively for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements. |
Sources and references
- [1] U.S. FDA multidisciplinary review for bremelanotide.
- [2] PubChem. Bremelanotide compound record.
- [3] DailyMed. Bremelanotide acetate product information.
Frequently Asked Questions
Do the CAS number and PubChem CID apply to every batch form?
Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.
What does an analytical purity result mean?
It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.
How should the material be stored and handled?
Follow the exact label, batch CoA and SDS together with the institution's risk assessment. Use only storage and stability information linked to the exact material form and batch.